Natco Pharma has announced the launch of its generic version of Pomalidomide capsules in the United States, marking a significant expansion of its oncology and specialty medicine portfolio. The product, introduced in partnership with Breckenridge Pharmaceutical, Inc., is aimed at improving affordability and access for patients undergoing treatment for serious blood cancers.
Natco Pharma’s newly launched Pomalidomide capsules are the generic equivalent of Pomalyst, originally developed by Celgene. The medication is primarily prescribed for the treatment of certain blood and bone marrow cancers, including multiple myeloma.
The generic capsules are available in four strengths — 1mg, 2mg, 3mg, and 4mg — providing physicians flexibility in tailoring dosage to individual patient requirements. According to the company’s regulatory filing, the product will be distributed mainly through specialty pharmacies and clinics across the United States.
Pomalidomide capsules are indicated for adult patients diagnosed with multiple myeloma who have undergone at least two prior therapies. These prior treatments must include lenalidomide and a proteasome inhibitor, and the patient must have shown disease progression either during treatment or within 60 days after completing their last therapy.
In addition to multiple myeloma, the drug is also approved for:
AIDS-related Kaposi sarcoma in patients who have not responded adequately to highly active antiretroviral therapy (HAART).
HIV-negative adult patients diagnosed with Kaposi sarcoma.
These approvals expand the medication’s scope, offering therapeutic options for patients facing complex and advanced-stage conditions.
Commenting on the launch, Rajeev Nannapaneni, Vice Chairman and CEO of Natco Pharma, emphasized that the introduction of generic Pomalidomide strengthens the company’s oncology and specialty portfolio in the US market.
He noted that the launch reflects Natco’s long-term commitment to improving global access to specialty medicines. According to him, expanding into complex and high-value therapeutic areas remains a strategic priority for the company.
Natco has steadily built its presence in regulated markets by focusing on niche and specialty products that address unmet medical needs. The addition of Pomalidomide further reinforces its capabilities in the oncology segment.
Breckenridge Pharmaceutical, Inc., Natco’s marketing and distribution partner in the United States, underscored the importance of affordability in specialty treatments.
Brian Guy, President and Chief Commercial Officer at Breckenridge, stated that the launch delivers a high-quality and cost-effective generic solution. He also highlighted that copay assistance programs will be available for eligible patients to help minimize financial barriers and prevent treatment interruptions.
Access and affordability remain significant challenges for patients relying on specialty therapies, particularly in oncology, where treatment costs can be substantial. By offering a generic alternative, the partnership aims to ease the economic burden on patients and healthcare systems.
According to industry sales data cited by Natco Pharma, Pomalidomide capsules in the 1mg, 2mg, 3mg, and 4mg strengths recorded estimated US sales of approximately USD 3.2 billion for the 12 months ending September 2025.
This sizable market opportunity underscores the commercial significance of the launch. Generic competition in such high-value therapeutic segments often leads to reduced treatment costs and increased patient access, benefiting both payers and patients.
The US remains one of the largest pharmaceutical markets globally, and successful product launches in this region can substantially enhance revenue streams for generic manufacturers.
The launch aligns with Natco Pharma’s broader strategy of focusing on specialty and complex generic medicines rather than purely volume-driven products. Complex generics often involve advanced manufacturing processes, regulatory expertise, and strong clinical understanding.
By targeting niche segments such as oncology and rare diseases, Natco differentiates itself in an increasingly competitive pharmaceutical landscape.
The company has also indicated plans to introduce more complex specialty products in the coming years, further strengthening its pipeline and global footprint.
Conclusion
Natco Pharma’s launch of generic Pomalidomide capsules in the US marks a significant milestone in its oncology expansion strategy. In partnership with Breckenridge Pharmaceutical, the company aims to enhance patient access to high-quality and affordable treatment options for multiple myeloma and Kaposi sarcoma.
With strong market demand and a growing specialty portfolio, Natco continues to position itself as a key player in the global generics and oncology segment.